{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T10:18:19Z","timestamp":1720779499913},"reference-count":82,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.bulcan.2017.05.010","type":"journal-article","created":{"date-parts":[[2017,11,23]],"date-time":"2017-11-23T01:46:43Z","timestamp":1511401603000},"page":"S121-S130","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S","title":["Allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques dans les lymphomes indolents\u00a0: recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)"],"prefix":"10.1016","volume":"104","author":[{"given":"Jordan","family":"Gauthier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Chantepie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krimo","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar","family":"Jost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Claire","family":"Gac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gandhi","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9my","family":"Dul\u00e9ry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricette","family":"Michallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00e9my","family":"Delage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Lewalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Cornillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bulcan.2017.05.010_bib0005","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2017.05.010_bib0010","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.bbmt.2015.05.007","article-title":"Impact of pretransplantation (18)F-fluorodeoxy glucose-positron emission tomography status on outcomes after allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma","volume":"21","author":"Bachanova","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bulcan.2017.05.010_bib0015","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.bbmt.2016.03.034","article-title":"Impact of pretransplantation (18)F-fluorodeoxyglucose-positron emission tomography on survival outcomes after T cell-depleted allogeneic transplantation for Hodgkin lymphoma","volume":"22","author":"Reyal","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2017.05.010_bib0020","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1148\/radiol.2015142556","article-title":"Prognostic value of FDG PET\/CT before allogeneic and autologous stem cell transplantation for aggressive lymphoma","volume":"277","author":"Ulaner","year":"2015","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.bulcan.2017.05.010_bib0025","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bbmt.2008.01.008","article-title":"Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome","volume":"14","author":"Armand","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.bulcan.2017.05.010_bib0030","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/sj.leu.2404822","article-title":"Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome","volume":"21","author":"Corradini","year":"2007","journal-title":"Leukemia"},{"issue":"29","key":"10.1016\/j.bulcan.2017.05.010_bib0035","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11S","key":"10.1016\/j.bulcan.2017.05.010_bib0040","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"[How we harmonize HSCT clinical practices among the SFGM-TC centers]","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2017.05.010_bib0045","first-page":"1832","article-title":"Allogeneic bone marrow transplantation for low-grade lymphoma","volume":"92","author":"van Besien","year":"1998","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bulcan.2017.05.010_bib0050","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdg200","article-title":"Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma","volume":"14","author":"Hosing","year":"2003","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.bulcan.2017.05.010_bib0055","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1200\/JCO.2002.11.088","article-title":"Role of nonmyeloablative allogeneic stem cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies","volume":"20","author":"Branson","year":"2002","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2017.05.010_bib0060","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/sj.bmt.1700781","article-title":"Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect","volume":"19","author":"van Besien","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bulcan.2017.05.010_bib0065","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/sj.bmt.1704290","article-title":"Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation","volume":"32","author":"Mandigers","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bulcan.2017.05.010_bib0070","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3324\/haematol.2013.084723","article-title":"Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party","volume":"98","author":"Montoto","year":"2013","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.bulcan.2017.05.010_bib0075","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.bulcan.2017.05.010_bib0080","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1002\/cncr.28243","article-title":"Stem cell transplantation for follicular lymphoma relapsed\/refractory after prior rituximab","volume":"119","author":"Evens","year":"2013","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.bulcan.2017.05.010_bib0085","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/bmt.2012.10","article-title":"Long-term outcome after autologous or allogeneic stem cell transplantation in patients with recurrent follicular lymphoma","volume":"47","author":"Reddy","year":"2012","journal-title":"Bone marrow Transplant"},{"issue":"8","key":"10.1016\/j.bulcan.2017.05.010_bib0090","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","article-title":"An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation","volume":"31","author":"Peniket","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bulcan.2017.05.010_bib0095","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.bbmt.2015.07.028","article-title":"Reduced-intensity allografting as first transplantation approach in relapsed\/refractory grades one and two follicular lymphoma provides improved outcomes in long-term survivors","volume":"21","author":"Klyuchnikov","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.bulcan.2017.05.010_bib0100","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/bmt.2013.83","article-title":"The outcome of reduced-intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT","volume":"48","author":"Robinson","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2017.05.010_bib0105","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/bjh.13947","article-title":"The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of\u00a0\u2264\u00a012\u00a0months","volume":"173","author":"Lunning","year":"2016","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.bulcan.2017.05.010_bib0110","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.bbmt.2010.11.004","article-title":"Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response","volume":"17","author":"Tomblyn","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2017.05.010_bib0115","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","article-title":"Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning","volume":"14","author":"Hari","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bulcan.2017.05.010_bib0120","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.bbmt.2006.08.035","article-title":"Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma","volume":"12","author":"Rodriguez","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2017.05.010_bib0125","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.bbmt.2013.01.024","article-title":"Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma","volume":"19","author":"Hamadani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2017.05.010_bib0130","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2141.2009.07905.x","article-title":"Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"147","author":"Avivi","year":"2009","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.bulcan.2017.05.010_bib0135","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/ajh.23246","article-title":"Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B cell lymphoma associated with follicular lymphoma, or de novo diffuse large B cell lymphoma","volume":"87","author":"Tada","year":"2012","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.bulcan.2017.05.010_bib0140","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.2012.44.0693","article-title":"Autologous and allogeneic stem cell transplantation for transformed follicular lymphoma: a report of the Canadian Blood and Marrow Transplant Group","volume":"31","author":"Villa","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2017.05.010_bib0145","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.bbmt.2014.03.014","article-title":"Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma","volume":"20","author":"Wirk","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.bulcan.2017.05.010_bib0150","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bulcan.2017.05.010_bib0155","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.bulcan.2017.05.010_bib0160","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","article-title":"Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial","volume":"34","author":"Sarkozy","year":"2016","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.bulcan.2017.05.010_bib0165","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link","year":"2013","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.bulcan.2017.05.010_bib0170","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2015-11-624288","article-title":"Follicular lymphoma: evolving therapeutic strategies","volume":"127","author":"Kahl","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bulcan.2017.05.010_bib0175","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bulcan.2017.05.010_bib0180","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.bbmt.2016.04.014","article-title":"Reduced-intensity conditioning with fludarabine, cyclophosphamide, and high-dose rituximab for allogeneic hematopoietic cell transplantation for follicular lymphoma: a phase two multicenter trial from the Blood and Marrow Transplant Clinical Trials Network","volume":"22","author":"Laport","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2017.05.010_bib0185","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.bbmt.2013.11.029","article-title":"A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients","volume":"20","author":"Sauter","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"10.1016\/j.bulcan.2017.05.010_bib0190","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2017.05.010_bib0195","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bulcan.2017.05.010_bib0200","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"30","key":"10.1016\/j.bulcan.2017.05.010_bib0205","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2007.15.4757","article-title":"Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"26","author":"Sorror","year":"2008","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.bulcan.2017.05.010_bib0210","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.2003.12.011","article-title":"Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem cell transplantation: the Cooperative German Transplant Study Group","volume":"21","author":"Schetelig","year":"2003","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.bulcan.2017.05.010_bib0215","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2005-05-1778","article-title":"Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia","volume":"106","author":"Gribben","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2017.05.010_bib0220","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.leu.2404441","article-title":"Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus","volume":"21","author":"Dreger","year":"2007","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bulcan.2017.05.010_bib0225","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.exphem.2012.10.008","article-title":"Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study","volume":"41","author":"Michallet","year":"2013","journal-title":"Exp Hematol"},{"issue":"2","key":"10.1016\/j.bulcan.2017.05.010_bib0230","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/leu.2012.228","article-title":"Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome","volume":"27","author":"Brown","year":"2013","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.bulcan.2017.05.010_bib0235","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1002\/cncr.26091","article-title":"Nonmyeloablative allogeneic stem cell transplantation in relapsed\/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome","volume":"117","author":"Khouri","year":"2011","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2017.05.010_bib0240","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/annonc\/mdt511","article-title":"The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison","volume":"25","author":"Herth","year":"2014","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2017.05.010_bib0245","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/bmt.2012.71","article-title":"Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis","volume":"47","author":"Kharfan-Dabaja","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.bulcan.2017.05.010_bib0250","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2013-07-515361","article-title":"Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)","volume":"123","author":"Woyach","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bulcan.2017.05.010_bib0255","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.bulcan.2017.05.010_bib0260","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1182\/blood-2014-07-586826","article-title":"Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?","volume":"124","author":"Dreger","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bulcan.2017.05.010_bib0265","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.bbmt.2016.09.013","article-title":"Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation","volume":"22","author":"Kharfan-Dabaja","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bulcan.2017.05.010_bib0270","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/bmt.2016.9","article-title":"Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study","volume":"51","author":"van Gelder","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"10.1016\/j.bulcan.2017.05.010_bib0275","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1200\/JCO.2011.37.4108","volume":"30","author":"Cwynarski","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10044","key":"10.1016\/j.bulcan.2017.05.010_bib0280","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bulcan.2017.05.010_bib0285","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2014.223","article-title":"The EBMT\/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma","volume":"29","author":"Robinson","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bulcan.2017.05.010_bib0290","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/annonc\/mdu097","article-title":"Outcome and prognostic factors in patients with mantle cell lymphoma relapsing after autologous stem cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"25","author":"Dietrich","year":"2014","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2017.05.010_bib0295","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"issue":"10020","key":"10.1016\/j.bulcan.2017.05.010_bib0300","first-page":"770","volume":"387","author":"Dreyling","year":"2016","journal-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet"},{"issue":"6","key":"10.1016\/j.bulcan.2017.05.010_bib0305","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.bulcan.2017.05.010_bib0310","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.2217\/fon-2016-0146","article-title":"Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review","volume":"12","author":"Kharfan-Dabaja","year":"2016","journal-title":"Future Oncol"},{"issue":"18","key":"10.1016\/j.bulcan.2017.05.010_bib0315","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the M.D.\u00a0Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bulcan.2017.05.010_bib0320","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/bmt.2016.102","article-title":"Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC","volume":"51","author":"Tessoulin","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2017.05.010_bib0325","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/ejh.12442","article-title":"Role of allogeneic stem cell transplantation in mantle cell lymphoma","volume":"94","author":"Cohen","year":"2015","journal-title":"Eur J Haematol"},{"issue":"10","key":"10.1016\/j.bulcan.2017.05.010_bib0330","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/bmt.2015.156","article-title":"Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era","volume":"50","author":"Mussetti","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"20","key":"10.1016\/j.bulcan.2017.05.010_bib0335","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.29498","article-title":"Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"121","author":"Vaughn","year":"2015","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2017.05.010_bib0340","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2013.01.009","article-title":"Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research","volume":"19","author":"Hamadani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.bulcan.2017.05.010_bib0345","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.bbmt.2010.04.006","article-title":"Outcome following reduced-intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation","volume":"16","author":"Cook","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2017.05.010_bib0350","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/sj.bmt.1705702","article-title":"Long-term graft-versus-Waldenstr\u00f6m macroglobulinemia effect following reduced-intensity conditioning allogeneic stem cell transplantation","volume":"40","author":"Meniane","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2017.05.010_bib0355","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/sj.bmt.1705748","article-title":"Evidence of graft-versus-Waldenstr\u00f6m's macroglobulinaemia effect after allogeneic stem cell transplantation: a single centre experience","volume":"40","author":"Stakiw","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"33","key":"10.1016\/j.bulcan.2017.05.010_bib0360","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1200\/JCO.2009.27.3607","article-title":"Allogeneic stem cell transplantation in patients with Waldenstr\u00f6m macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Kyriakou","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2017.05.010_bib0365","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bbmt.2016.10.010","article-title":"Allogeneic transplantation for relapsed Waldenstr\u00f6m macroglobulinemia and lymphoplasmacytic lymphoma","volume":"23","author":"Cornell","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bulcan.2017.05.010_bib0370","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3324\/haematol.2009.017814","article-title":"Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstr\u00f6m's macroglobulinemia. Results of a retrospective analysis of the Soci\u00e9t\u00e9 fran\u00e7aise de greffe de moelle et de th\u00e9rapie cellulaire","volume":"95","author":"Garnier","year":"2010","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.bulcan.2017.05.010_bib0375","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.leukres.2010.04.005","article-title":"Validation of the International Prognostic Scoring System (IPSS) for Waldenstr\u00f6m's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)","volume":"34","author":"Kastritis","year":"2010","journal-title":"Leuk Res"},{"issue":"10","key":"10.1016\/j.bulcan.2017.05.010_bib0380","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1182\/blood-2016-04-711234","article-title":"Treatment recommendations from the Eighth International Workshop on Waldenstr\u00f6m's macroglobulinemia","volume":"128","author":"Leblond","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bulcan.2017.05.010_bib0385","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/sj.bmt.1703625","article-title":"Allogeneic bone marrow transplantation in patients with follicular lymphoma: a single-center study","volume":"30","author":"Yakoub-Agha","year":"2002","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.bulcan.2017.05.010_bib0390","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.bbmt.2011.01.016","article-title":"Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901","volume":"17","author":"Shea","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bulcan.2017.05.010_bib0395","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3324\/haematol.2009.017608","article-title":"Reduced-intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials","volume":"95","author":"Pinana","year":"2010","journal-title":"Haematologica"},{"issue":"26","key":"10.1016\/j.bulcan.2017.05.010_bib0400","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1182\/blood-2012-03-417808","article-title":"Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results","volume":"119","author":"Khouri","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bulcan.2017.05.010_bib0405","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma","volume":"26","author":"Rezvani","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2017.05.010_bib0410","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3324\/haematol.10924","article-title":"Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)","volume":"92","author":"Vigouroux","year":"2007","journal-title":"Haematologica"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745511730276X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745511730276X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T03:11:15Z","timestamp":1531105875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745511730276X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":82,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S000745511730276X"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2017.05.010","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques dans les lymphomes indolents\u00a0: recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2017.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}